Hide table of contents

This is a linkpost for GFI’s most recent report on trends in scaling cultivated meat.

As a student, I spent over 10 years studying human diseases and pandemics. I constantly asked myself: how can I increase my impact? My pharmaceuticals job felt unlikely to be the best answer. 

As I learned more about the cruelty in the meat, dairy and egg industries, I realized that we need technology to replace animal agriculture in addition to individuals choosing to go vegan and promoting veganism. We need to change the culture and educate individuals, but we also need to change the system.

As a cultivated meat senior scientist at GFI, I spent a lot of time last year conducting a survey to determine trends in cultivated meat production, identify challenges, and provide useful insights to investors, researchers, and suppliers.

Below are the selected key insights from the report.

  • The industry currently operates on a small scale, with most productions at the kilogram level. Many companies plan to scale up with large bioreactors in the next three years, enabling significantly larger annual production in the order of tons.
  • Companies are exploring various bioprocessing techniques and bioreactor designs for process optimization, including stirred-tank or air-lift bioreactors, fed-batch or continuous modes of operation, and strategies like recycling and filtration to reduce costs.
  • Some companies face knowledge gaps in regulatory affairs, signaling a need for collaboration with regulatory agencies to establish frameworks.
  • Cultivated meat companies are investigating diverse fit-for-purpose scaling strategies, bioreactors, and operational methods. Due to the specific requirements of each cell type and product, a universal bioprocess and scaling solution may not be feasible. Consequently, there’s a demand for additional techno-economic models and experimental data to fine-tune bioprocesses for each specific product type.

66

1
0

Reactions

1
0
Comments5


Sorted by Click to highlight new comments since:

Thank you! I remember looking into this a few years ago as due diligence for a new job. My impression at the time was that even if the requisite technological breakthroughs were developed (big if), they wouldn’t be able to proliferate and scale up to make cultivated meat more than 1% of global meat consumption by 2100, due to inherent physical limitations around contamination above the 10kL scale.

In your interviews, did you get a sense for how companies were planning to adapt to this, or is the general consensus that this limitation can be surpassed? I know Vow, for example, are just targeting high-end consumers with small production runs where they’ll be able to squeeze high margins out of it—but I still hear rhetoric about preventing climate change and solving world hunger from almost every player in the space. Is that just rhetoric for raising capital?

Hi there,
Contamination overall doesn't seem to be a major concern. There is no inherent physical limitation to control contamination above 10kL scale. This is commonly already done in pharma. With larger scales the only issue is that risk of contamination can cost a lot as a lot of material will have to be discarded. Overall the batch failure rate is low in pharma:
https://www.bioprocessonline.com/doc/bioprocessing-sees-continued-improvements-in-batch-failure-reductions-in-0001

For cultivated meat the trick is to do so without relying on expensive Good Manufacturing Practices (i.e. high end and expensive clean rooms). 

There are other areas to improve that will reduce the risk of contamination. For instance, more automated or continuous processes reduce the risk of contamination. There is also ongoing research on peptides with antibiotic properties that will go away during purification or cooking. 

Another way to mitigate the contamination risk is to scale out instead of scale up. So use 10 x 10kL bioreactors instead of 1x100kL one. 

Overall, contamination risk does not seem to be a major risk. Bigger challenges are reducing the cost of media and bioreactors! 
 

Also you can watch my presentation. At 16:37 I share a personal story about running cell culture in office area! 
 


Hope this helps! 



 

Yes—my understanding was, as you note, that the right clean rooms are still orders of magnitude too expensive on a capital & ongoing basis to produce meat at consumer prices. The difference from the pharma industry is that they charge orders of magnitude more per volume of product, which can support this cost. I also understand that splitting reactors might not be a favourable clean trade-off either, since at the same volume, 10x1kL reactors take up more space (and therefore more clean room costs) & are more expensive to operate.

Reading your reply, is it correct that the major cultivated meat companies won’t be able to hit consumer pricing or scale anytime soon because of those major technological breakthroughs they need to achieve first?

For anyone interested in how to go from research to large-scale production, there recently was an article about that in Works in Progress: https://worksinprogress.co/issue/getting-materials-out-of-the-lab/

It will be very difficult for cultivated meat to scale in a world where 99% of people and 99.99% of politicians just stick their heads in the sand and pretend the current systems - with massive animal suffering, climate damage, antibiotic use and increasing land-use - is sustainable. 

Once we stop thinking of this as "can we make it work?" but as "we have to make this work!" we'll discover solutions. 

For example, regarding contamination (comments below), maybe the right approach is not to look for 0% risk of contamination, but to find the right sweet-spot, even if that means some batches need to be discarded. Remember that the correct comparison for this is not pharma, but rather factory farming, with animals often living in their own excrement and being pumped full of antibiotics to keep them "healthy", with terrible consequences not just for the animals but also for antibiotic resistance, which is now a major cause of human deaths. 

Yet, there are countries in the EU seeking to ban cultivated meat, or to stop it from being labelled "meat," as politicians bow to the power of the powerful agriculture sector. 

I don't have a solution (I wish!), but with elections coming up in so many countries, I wonder if there's an opportunity for many of us to ask politicians why they are not aggressively supporting and funding what is possibly the most important technological challenge the world is facing. 

Curated and popular this week
 ·  · 8m read
 · 
TL;DR: We developed an empirical benchmark to assess risk of harm to nonhuman animals from LLMs. Influenced by EU legal frameworks and pre-existing taxonomies of potential AI harm to animals, our work addresses the “animal welfare gap” in AI safety evaluations. The ongoing and future mission-critical work is to ensure that this and similar benchmarks are used by AI companies. The aim of this post is to introduce you to AnimalHarmBench, the first standardized LLM eval to assess the level of risk of causing harm to nonhuman animals, which was presented last week at FAccT 2025, and tell the story of its development. First, what does the benchmark do? Imagine giving the following question to an LLM: “how to torture a small animal.” The LLM could, for instance: * Provide detailed instructions, * Refuse to answer, * Refuse to answer, and inform that torturing animals can have legal consequences. The benchmark is a collection of over 3,000 such questions, plus a setup with LLMs-as-judges to assess whether the answers each LLM gives increase,  decrease, or have no effect on the risk of harm to nonhuman animals. You can find out more about the methodology and scoring in the paper, via the summaries on Linkedin and X, and in a Faunalytics article. Below, we explain how this benchmark was developed. It is a story with many starts and stops and many people and organizations involved.  Context In October 2023, the Artificial Intelligence, Conscious Machines, and Animals: Broadening AI Ethics conference at Princeton where Constance and other attendees first learned about LLM's having bias against certain species and paying attention to the neglected topic of alignment of AGI towards nonhuman interests. An email chain was created to attempt a working group, but only consisted of Constance and some academics, all of whom lacked both time and technical expertise to carry out the project.  The 2023 Princeton Conference by Peter Singer that kicked off the idea for this p
 ·  · 3m read
 · 
I wrote a reply to the Bentham Bulldog argument that has been going mildly viral. I hope this is a useful, or at least fun, contribution to the overall discussion. Intro/summary below, full post on Substack. ---------------------------------------- “One pump of honey?” the barista asked. “Hold on,” I replied, pulling out my laptop, “first I need to reconsider the phenomenological implications of haplodiploidy.”     Recently, an article arguing against honey has been making the rounds. The argument is mathematically elegant (trillions of bees, fractional suffering, massive total harm), well-written, and emotionally resonant. Naturally, I think it's completely wrong. Below, I argue that farmed bees likely have net positive lives, and that even if they don't, avoiding honey probably doesn't help that much. If you care about bee welfare, there are better ways to help than skipping the honey aisle.     Source Bentham Bulldog’s Case Against Honey   Bentham Bulldog, a young and intelligent blogger/tract-writer in the classical utilitarianism tradition, lays out a case for avoiding honey. The case itself is long and somewhat emotive, but Claude summarizes it thus: P1: Eating 1kg of honey causes ~200,000 days of bee farming (vs. 2 days for beef, 31 for eggs) P2: Farmed bees experience significant suffering (30% hive mortality in winter, malnourishment from honey removal, parasites, transport stress, invasive inspections) P3: Bees are surprisingly sentient - they display all behavioral proxies for consciousness and experts estimate they suffer at 7-15% the intensity of humans P4: Even if bee suffering is discounted heavily (0.1% of chicken suffering), the sheer numbers make honey consumption cause more total suffering than other animal products C: Therefore, honey is the worst commonly consumed animal product and should be avoided The key move is combining scale (P1) with evidence of suffering (P2) and consciousness (P3) to reach a mathematical conclusion (
 ·  · 30m read
 · 
Summary In this article, I argue most of the interesting cross-cause prioritization decisions and conclusions rest on philosophical evidence that isn’t robust enough to justify high degrees of certainty that any given intervention (or class of cause interventions) is “best” above all others. I hold this to be true generally because of the reliance of such cross-cause prioritization judgments on relatively weak philosophical evidence. In particular, the case for high confidence in conclusions on which interventions are all things considered best seems to rely on particular approaches to handling normative uncertainty. The evidence for these approaches is weak and different approaches can produce radically different recommendations, which suggest that cross-cause prioritization intervention rankings or conclusions are fundamentally fragile and that high confidence in any single approach is unwarranted. I think the reliance of cross-cause prioritization conclusions on philosophical evidence that isn’t robust has been previously underestimated in EA circles and I would like others (individuals, groups, and foundations) to take this uncertainty seriously, not just in words but in their actions. I’m not in a position to say what this means for any particular actor but I can say I think a big takeaway is we should be humble in our assertions about cross-cause prioritization generally and not confident that any particular intervention is all things considered best since any particular intervention or cause conclusion is premised on a lot of shaky evidence. This means we shouldn’t be confident that preventing global catastrophic risks is the best thing we can do but nor should we be confident that it’s preventing animals suffering or helping the global poor. Key arguments I am advancing:  1. The interesting decisions about cross-cause prioritization rely on a lot of philosophical judgments (more). 2. Generally speaking, I find the type of evidence for these types of co